Aptobio Receives FDA Approval to Resume Phase I Clinical Trial for ABF-101

Aptobio (ticker: 293780), a biopharmaceutical company developing inflammation-suppressing and anti-cancer drugs, announced on June 16 that it has received FDA approval to restart Phase I clinical trials for ABF-101. The trial will evaluate oral administration safety, bioavailability, and pharmacokinetics in healthy volunteers and age-related macular degeneration (AMD) patients. Following the FDA's removal of the Clinical Hold, the previously suspended Phase I trial and dosing will resume. Aptobio's stock closed at 5,010 won, up 2.14% from the previous day. As of its most recent financial statements, the company reported total assets of 600 billion won, total liabilities of 128 billion won, and total equity of 472 billion won. Revenue was 37 billion won, with an operating loss of 158 billion won and a net loss of 163 billion won. Aptobio, a natural science and engineering R&D firm, listed on KOSDAQ on July 24, 2009.